A Safety and Efficacy Trial of Vaccine Boosting With Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Pancreatic cancer DNA vaccine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 20 Aug 2021 Biomarkers information updated
- 29 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov
- 18 Dec 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.